[mkdf_section_title position=”” show_separator=”yes” separator_position=”center” title_tag=”” disable_break_words=”no” title=”Pubblicazioni 2007″ holder_padding=”13px”]
Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.
Falanga A, Rickles FR.
Hematology Am Soc Hematol Educ Program. 2007:165-71.
Heparin in tumor progression and metastatic dissemination.
Falanga A, Marchetti M.
Semin Thromb Hemost. 2007;33(7):688-94.
V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.
Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T.
Exp Hematol. 2007 Sep;35(9):1476.
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW; American Society of Clinical Oncology.
J Clin Oncol. 2007;25(34):5490-505.